Literature DB >> 8156505

Recurrent renal salt wasting in a child treated with carboplatin and etoposide.

C Tscherning1, H Rubie, A Chancholle, S Claeyssens, A Robert, J Fabre, F Bouissou.   

Abstract

BACKGROUND: Nephrotoxicity of carboplatin is rare, especially in children with normal renal function. A 3-year-old boy had localized esthesioneuroblastoma and received 2 courses of carboplatin (200 mg/m2/day during a 1-hour infusion for 3 consecutive days) associated with etoposide (150 mg/m2/day after carboplatin). Because of a good tumor response, a second course was given 21 days later. Complete surgical excision and local irradiation were performed. However, the tumor recurred a few months later, and the patient subsequently died of the disease.
METHODS: Renal function initially was assessed by standard baseline chemistry and technetium-panetetic acid (Tc-DTPA) clearance. Follow-up included ionic controls and tubular exploration during the episodes of hyponatremia.
RESULTS: Hyponatremia occurred 4 days after completion of the first course and resolved after intravenous supplementation. It recurred 20 days after the second course despite salt and magnesium prehydration and posthydration and resolved 17 days later. No glomerular dysfunction was noticed. The association of urinary bicarbonate loss with elevated N-acetyl-beta-glucosaminidase suggested a proximal tubular damage.
CONCLUSIONS: Standard doses of carboplatin may lead to recurrent renal salt wasting in children with initially normal renal function.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8156505     DOI: 10.1002/1097-0142(19940315)73:6<1761::aid-cncr2820730635>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Nanoparticle-aided Radiotherapy for Retinoblastoma and Choroidal Melanoma.

Authors:  Yucel Altundal; Erno Sajo; G Mike Makrigiorgos; Ross I Berbeco; Wilfred Ngwa
Journal:  IFMBE Proc       Date:  2015

Review 2.  Hyponatremia related to medical anticancer treatment.

Authors:  T Berghmans
Journal:  Support Care Cancer       Date:  1996-09       Impact factor: 3.603

3.  Phase I/II Trial of Paclitaxel With Ifosfamide Followed by High-Dose Paclitaxel, Ifosfamide, and Carboplatin (TI-TIC) With Autologous Stem Cell Reinfusion for Salvage Treatment of Germ Cell Tumors.

Authors:  Darren R Feldman; Ilya Glezerman; Sujata Patil; Lindsay Van Alstine; Dean F Bajorin; Patricia Fischer; Amanad Hughes; Joel Sheinfeld; Manjit Bains; Lilian Reich; Kaitlin Woo; Sergio Giralt; George J Bosl; Robert J Motzer
Journal:  Clin Genitourin Cancer       Date:  2015-05-16       Impact factor: 2.872

Review 4.  Mechanisms of Cisplatin nephrotoxicity.

Authors:  Ronald P Miller; Raghu K Tadagavadi; Ganesan Ramesh; William Brian Reeves
Journal:  Toxins (Basel)       Date:  2010-10-26       Impact factor: 4.546

5.  Dose-related nephrotoxicity of carboplatin in children.

Authors:  M W English; R Skinner; A D Pearson; L Price; R Wyllie; A W Craft
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

6.  Validity of Weekly Administration of Carboplatin after Carboplatin-Induced SIADH: Two Case Reports and Literature Review.

Authors:  Suguru Fujitsuka; Naoki Horikawa; Teruki Yoshida; Sae Yu; Ryosuke Kuroda; Mitsuru Tsuji; Maki Umemiya; Rei Gou; Yoshihide Inayama; Hirohiko Tani; Kenzo Kosaka
Journal:  Case Rep Oncol       Date:  2022-03-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.